Renaissance Capital logo

AXSM News

Going to great pains: Grünenthal acquires Thar Pharmaceuticals, which pulls $50 million IPO

THAR

Thar Pharmaceuticals, which is developing novel oral therapies for chronic pain utilizing the 505(b)(2) pathway, withdrew its plans for an initial public offering on Wednesday. It originally filed in August 2016 with a proposed deal size of $50 million. Competitor Axsome Therapeutics (AXSM; -18%) raised $51 million in a November 2015 IPO. The Pittsburgh,...read more

US IPO Weekly Recap: Payments unicorn Square gains 43% after slashing price

SQ

All five IPOs priced at the low end or below the range this week but finished Friday with a positive return. That dynamic has become more common for IPOs in the past 90 days. ...read more

Axsome Therapeutics prices IPO below the range at $9; finishes Thursday down 3%

AXSM

Axsome Therapeutics, which is developing novel therapies for pain and CNS disorders utilizing the 505(b)(2) pathway, raised $51 million on Thursday by offering 5.67 million shares at $9. At $9 per share, the biotech went public at a market cap of $180 million. Axsome had originally planned to raise $51 million by offering 4.25 million shares at $11 to $13, with a proposed...read more

Week ahead: Ten deals set to raise $1.5 billion

SQ

In a week that could see ten IPOs, only one is a biotech. Next week, there are profitable, cash-flow positive companies; there are tech companies ranging from payment processing to email security; there are two companies that aim for customers in the great outdoors; and there are...read more